The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
The ruling Liberal Democratic Party (LDP) is considering including a project to forge a clinical development platform using a patient registry in the government’s economic growth strategy to be updated in June. The Ministry of Health, Labor and Welfare (MHLW)…
To read the full story
Related Article
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- MHLW Global Strategy Aims at Regulatory Shortcut for Japan-OK’ed Drugs
June 29, 2015
- Draft Growth Strategy Embraces Clinical Development Infrastructure, Drops Numerical Target for Sakigake System
June 23, 2015
- LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
- Health Ministry Eyes Future Genomic Data Registration at National Medical Centers
October 21, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
REGULATORY
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
- Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
- MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
- Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…